LETERMOVIR (MK-8228) VERSUS PLACEBO IN THE PREVENTION OF CLINICALLY-SIGNIFICANT CYTOMEGALOVIRUS (CMV) INFECTION IN ADULT, CMV-SEROPOSITIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS (MK-8228-001):